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Method

INTEGRATE: gene fusion discovery using whole
genome and transcriptome data
Jin Zhang,1,2 Nicole M. White,2 Heather K. Schmidt,1 Robert S. Fulton,1,3 Chad
Tomlinson,1 Wesley C. Warren,1 Richard K. Wilson,1,3 and Christopher A. Maher1,2,4,5
1

McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri 63110, USA; 2Department of Internal
Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, Missouri 63110, USA; 3Department of Genetics,
Washington University School of Medicine, St. Louis, Missouri 63110, USA; 4Alvin J. Siteman Cancer Center, Washington University
School of Medicine, St. Louis, Missouri 63110, USA; 5Department of Biomedical Engineering, Washington University School of
Medicine, St. Louis, Missouri 63110, USA
While next-generation sequencing (NGS) has become the primary technology for discovering gene fusions, we are still faced
with the challenge of ensuring that causative mutations are not missed while minimizing false positives. Currently, there are
many computational tools that predict structural variations (SV) and gene fusions using whole genome (WGS) and transcriptome sequencing (RNA-seq) data separately. However, as both WGS and RNA-seq have their limitations when used
independently, we hypothesize that the orthogonal validation from integrating both data could generate a sensitive and
specific approach for detecting high-confidence gene fusion predictions. Fortunately, decreasing NGS costs have resulted
in a growing quantity of patients with both data available. Therefore, we developed a gene fusion discovery tool,
INTEGRATE, that leverages both RNA-seq and WGS data to reconstruct gene fusion junctions and genomic breakpoints
by split-read mapping. To evaluate INTEGRATE, we compared it with eight additional gene fusion discovery tools using the
well-characterized breast cell line HCC1395 and peripheral blood lymphocytes derived from the same patient (HCC1395BL).
The predictions subsequently underwent a targeted validation leading to the discovery of 131 novel fusions in addition to the
seven previously reported fusions. Overall, INTEGRATE only missed six out of the 138 validated fusions and had the highest
accuracy of the nine tools evaluated. Additionally, we applied INTEGRATE to 62 breast cancer patients from The Cancer
Genome Atlas (TCGA) and found multiple recurrent gene fusions including a subset involving estrogen receptor. Taken
together, INTEGRATE is a highly sensitive and accurate tool that is freely available for academic use.
[Supplemental material is available for this article.]
Chromosomal rearrangements represent the most prevalent category of somatic aberrations in cancer genomes, often leading to
the juxtaposition of two genes, creating gene fusions. Gene fusions
have served as exquisitely specific diagnostic markers, prognostic
indicators, and therapeutic targets (Druker et al. 2006). The unparalleled depth of next-generation sequencing (NGS) has revealed
novel gene fusions in numerous solid tumors as exemplified by
fusions involving the E26 transformation-specific (ETS) transcription factor family members in prostate cancer (Tomlins et
al. 2007), MAST and NOTCH kinases in breast cancer (Robinson
et al. 2011), and ALK, ROS1, and RET fusions in lung cancer
(Takeuchi et al. 2012).
To date, many groups have used whole-genome sequencing
(WGS) to identify structural variations (SV), a subset of which
may produce gene fusions. Despite some successes, existing bioinformatics tools such as BreakDancer (Chen et al. 2009),
VariationHunter (Hormozdiari et al. 2010), CREST (Wang et al.
2011), and PRISM (Jiang et al. 2012) are hindered by intra-tumor
heterogeneity, alignment to repetitive genomic sequences, technical artifacts (i.e., library preparation), poor coverage, and a large
number of false-positive calls owing to sequencing errors. The failure to predict some SVs using WGS data would therefore result in
the corresponding gene fusion product being missed. Additional-
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ly, it is unclear whether SVs predicted to produce a gene fusion
are expressed in the absence of RNA-seq expression data.
Therefore, many groups have focused on using RNA-seq for gene
fusion discovery as it enriches for expressed events that are more
likely to be functional.
Currently, many RNA-seq gene fusion discovery algorithms
utilize spanning reads (one read partially aligns to both genes
corresponding to the fusion junction) or encompassing reads
(each read of a pair aligns to a different gene, thereby surrounding
the fusion junction) such as TopHat-Fusion (Kim and Salzberg
2011), deFuse (McPherson et al. 2011a), ChimeraScan (Iyer et al.
2011), BreakFusion (Chen et al. 2012), FusionCatcher (Nicorici
et al. 2014), pyPRADA (Torres-Garcia et al. 2014), and TRUP
(Fernandez-Cuesta et al. 2015). However, despite the successful application of these algorithms to discover gene fusions, a recent
comparison of eight gene fusion discovery tools revealed a lot of
variability between callers. Most tools report a very high number
of false-positive chimeras (Carrara et al. 2013), highlighting the ongoing struggle to balance sensitivity and specificity of fusion detection. Some of the various factors contributing to false positives and
false negatives include artifacts and mapping errors in RNA-seq
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data, reliance on a comprehensive transcriptome reference, repetitive regions, and low-expressing gene fusions that may appear as
background signal. Furthermore, while a large portion of unmapped reads may represent sequencing errors, artifacts, or the
limitations of split-read mapping tools, it is possible that a subset
of these unmapped reads could represent critical reads spanning
the gene fusion junction. Therefore, more efficient split-read mapping methods are necessary to find these critical reads among the
potential noise.
While WGS or RNA-seq have their limitations when analyzed
independently, the orthogonal validation from integrating RNAseq and WGS could generate a sensitive and specific approach
for detecting high-confidence gene fusion predictions. Since
WGS and RNA-seq data are generated separately, presumably
they do not share the same artifacts and noise and therefore will
result in fewer false positives. This in turn will facilitate the prioritization of gene fusion predictions as biologically relevant gene
fusions that are often masked by false positives. Furthermore,
weak sequence evidence by both WGS and RNA-seq could help
detect gene fusions expressed at low levels that may have appeared
as background noise when analyzing only WGS or RNA-seq data.
In addition to improving gene fusion discovery, integrating WGS
and transcriptome data can provide evidence about the gene
fusion biology. For instance, recent studies have shown the importance of read-through chimeras, which involve two adjacent genes
in the same coding orientation, in multiple cancers (Maher et al.
2009; Zhang et al. 2012; Varley et al. 2014). When analyzing
RNA-seq data alone, a chimera transcript is typically classified as
a read-through based on the proximity and orientation of the
genes. However, it is not possible to rule out that the event is the
by-product of a focal deletion. Therefore, the presence or absence
of a genomic event by integrating WGS and RNA-seq could improve the classification of RNA chimeras.
In this study, we describe a new method, INTEGRATE, for detecting expressed gene fusions by leveraging the advantages of
both WGS and RNA-seq generated from the same individual.
Existing methods that use both whole-genome and RNA-seq
data include Comrad (McPherson et al. 2011b), nFuse (McPherson et al. 2012), and BreakTrans (Chen et al. 2013). Comrad
(McPherson et al. 2011b) is a dedicated gene fusion calling program that simultaneously uses both encompassing RNA-seq and
WGS paired reads. It uses an integer linear programming algorithm
to assign repetitive reads that minimizes differences of WGS
data sets, RNA-seq data sets, and the reference genome. nFuse
(McPherson et al. 2012) is a computational tool intended to identify complex genomic rearrangements from whole-genome data
with the help of transcriptome sequencing data. More recently,
BreakTrans (Chen et al. 2013) was developed to intersect predicted
gene fusions that correspond with SV nominations by analyzing
the output of independent gene fusion and SV prediction tools.
Here, we developed INTEGRATE, which simultaneously uses
both RNA-seq and WGS encompassing and spanning reads to focus on the discovery of expressed gene fusions. To prioritize expressed gene fusions caused by SVs, INTEGRATE first utilizes
mapped and unmapped RNA-seq reads followed by analysis of
WGS reads from tumor, and if available, a normal sample. To minimize run time and memory requirements without sacrificing accuracy, INTEGRATE uses discordant RNA-seq reads to construct a
gene fusion graph connecting genes involved in a putative fusion
event. This enables all of the unaligned RNA-seq reads that could
serve as spanning junction reads to undergo split-read mapping
against only the Burrows-Wheeler Transform (BWT) for the rele-

vant gene pair in the fusion graph instead of against the whole
genome or whole transcriptome (see Methods for details). The
gene fusion graph also avoids nominating false positives since
INTEGRATE realigns encompassing and spanning reads to only
the BWTs for the relevant gene pair in the graph, thereby decreasing spurious mappings that may occur when aligning to the
whole genome or whole transcriptome. Here, we will show that
INTEGRATE is an efficient gene fusion discovery tool that has
both high sensitivity and accuracy. INTEGRATE can be downloaded at https://sourceforge.net/projects/integrate-fusion/.

Results
Overview of INTEGRATE
INTEGRATE is designed to discover gene fusions using RNA-seq
and WGS paired-end sequencing reads properly aligned to the
reference genome in BAM format. Unlike many gene fusion tools
which are programmed to use a specific reads mapping tool,
INTEGRATE is implemented with the flexibility to use reads
aligned by different tools, including GSNAP (Wu and Nacu
2010), TopHat2 (Kim et al. 2013), and STAR (Dobin et al. 2013).
Since we are most interested in expressed gene fusions,
INTEGRATE first utilizes mapped and unmapped RNA-seq reads,
followed by analysis of WGS reads from tumor and, if available,
a normal sample. INTEGRATE uses two types of reads, encompassing and spanning reads. Encompassing reads are pairs of reads with
each in the pair aligned to a different gene, thereby surrounding
the fusion junctions or genomic breakpoints, and spanning reads
are reads partially aligned to both genes corresponding to a fusion
junction or both flanking regions of an SV. As shown in Figure 1,
INTEGRATE is comprised of the following steps: (1) Construct
gene fusion graph using discordant, or encompassing, RNA-seq
reads; (2) remove edges corresponding to discordant reads that
have a concordant suboptimal mapping or have low weights due
to excessive multimapping; (3) map previously unaligned RNAseq reads between gene nodes as split-reads to reconstruct fusion
junctions (Supplemental Fig. 1); (4) retrieve encompassing WGS
reads corresponding to focal regions surrounding fusion junctions;
and (5) map spanning WGS reads to focal regions with the guidance of encompassing WGS reads to reconstruct genomic breakpoints. Once completed, INTEGRATE outputs the gene fusion
candidates with the exact fusion junctions sorted according to
the quantity of supporting WGS and RNA-seq reads.
To prioritize gene fusion candidates, INTEGRATE reports fusions in tiers corresponding to the level of sequencing support
and potential biology (Supplemental Fig. 2). Tiers 1, 2, and 3 all
involve gene fusions with canonical exonic boundaries. Tier 1 candidates have the highest confidence as they have both encompassing and spanning RNA-seq and WGS reads supporting a gene
fusion. Tier 2 gene fusion candidates also have both WGS and
RNA-seq read support; however, they only have encompassing
WGS read support and lack spanning WGS reads. Tier 3 lacks
any WGS read support but has both encompassing and spanning
RNA reads. However, Tier 3 includes both non-read-through gene
fusions (Tier 3-nr) and read-throughs (Tier 3-r).

Application to HCC1395 breast cancer cells
To evaluate INTEGRATE, we used HCC1395 breast cancer cells
because both SVs and gene fusions have been previously characterized in this cell line (Stephens et al. 2009; Robinson et al. 2011;
Kalyana-Sundaram et al. 2012), multiple gene fusions have been
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Figure 1. Overview of INTEGRATE. (A) INTEGRATE establishes a gene fusion graph using encompassing RNA-seq reads (black lines) to connect nodes or
genes (blue rectangles). Edges of the fusion graph are removed following various filtering steps before undergoing a targeted split-read alignment involving
the remaining edges. Encompassing and spanning split-read realignment and mapping are performed on BWTs of gene nodes (Supplemental Fig. 1).
Encompassing WGS reads are retrieved from regions determined by spanning RNA-seq reads. Spanning WGS reads are aligned to the regions indicated
by encompassing WGS reads (steps indicated by green and purple arrows; also see B). (B) When encompassing (black) and spanning (red) RNA-seq reads
have been mapped to the genes involved in a gene fusion, the encompassing WGS reads (green) are expected from focal encompassing WGS regions
(green area) bounded by maximum insert size upstream of or downstream from the fusion junctions of the transcripts. The spanning WGS reads (purple)
are expected to align within focal WGS regions (orange area) bounded by fusion junction and maximum insert size downstream from the encompassing
WGS reads.

experimentally validated using qRT-PCR (Lambros et al. 2011),
and because of the availability of a matched B lymphoblast cell
line (HCC1395BL) to be used as our normal comparator. We sequenced ∼321 million tumor RNA-seq paired-end reads, ∼339 million tumor RNA-seq paired-end reads, ∼1884 million tumor WGS
paired-end reads (∼63× coverage), and ∼1031 million normal WGS
paired-end reads (∼34× coverage). INTEGRATE was run using the
RNA-seq reads aligned by GSNAP (Wu and Nacu 2010), TopHat2
(Kim et al. 2013), and STAR (Dobin et al. 2013). WGS reads were
aligned using BWA (Li and Durbin 2009). Interestingly, we found
that different alignment tools affected the final list of gene fusion
predictions. Using alignments from GSNAP, TopHat2, and STAR
and running INTEGRATE with default parameters (i.e., two encompassing RNA-seq reads), we discovered 110, 68, and 68 gene
fusion candidates, respectively.
To compare the performance of INTEGRATE to other available
algorithms, we reanalyzed the HCC1395 data with three WGS
and RNA-seq callers (Comrad [McPherson et al. 2011b], nFuse
[McPherson et al. 2012], and BreakTrans [Chen et al. 2013]) and
five commonly used and recently published RNA-seq gene fusion
tools (TopHat-Fusion [Kim and Salzberg 2011], ChimeraScan [Iyer
et al. 2011], FusionCatcher [Nicorici et al. 2014], pyPRADA
[Torres-Garcia et al. 2014], and TRUP [Fernandez-Cuesta et al.
2015]). BreakTrans was provided with fusion and SV candidates
called by BreakDancer (Chen et al. 2009). For all methods, common
false-positive gene fusion predictions were filtered (Methods) to
produce high-confidence predictions for each program. This resulted in a range of four to 110 gene fusion candidates across the
programs. An aggregate of the top gene fusion candidates nominated by each program resulted in 240 gene fusion candidates
(Supplemental Fig. 3; Supplemental Table 1). After applying our
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filtering steps, of the eight additional programs, nFuse nominated the most gene fusion candidates (n = 103). ChimeraScan,
FusionCatcher, TopHat-Fusion, and pyPRADA had a moderate
number of gene fusion candidates with 54, 36, 12, and 17, respectively. TRUP, Comrad, and BreakTrans nominated a limited number of gene fusion candidates with 6, 4, and 4, respectively.
Through our comprehensive analysis, we found that two previously reported gene fusions, KCNQ5-RIMS1 and BCAR3-ABCA4,
are not called by any of the nine methods. Subsequent manual inspection did not identify any supporting reads for the two missed
gene fusions (KCNQ5-RIMS1 and BCAR3-ABCA4) in our data set.
This is not surprising for KCNQ5 and RIMS1, as the DNA coverage
shows an obvious aberration but the expression levels of KCNQ5
and RIMS1 are very low (Supplemental Fig. 4). In contrast, the fusion between BCAR3 and ABCA4 was previously identified by
RNA-seq but was never detected by WGS or experimentally validated. Therefore, its absence in our data could suggest that it
may not be expressed in our data or it is a false positive.
INTEGRATE is the only program to detect all seven previously discovered gene fusions, whereas the other programs detected between 2 and 5 of these gene fusions.

Validation of HCC1395 gene fusions
To evaluate the accuracy of the predictions from all these methods,
we used cDNA-Capture (Methods; Cabanski et al. 2014) which
combines RNA-seq with an enrichment step using custom probes
targeting 240 gene fusion candidates (Supplemental Table 1). The
240 gene fusion candidates are an aggregate of the top gene fusion
candidates nominated by each program. As shown in Figure 2, we
experimentally validated 138 gene fusions (see Supplemental
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Figure 2. Gene fusion validation. Targeted cDNA-capture validation was attempted for 240 gene fusion candidates called by INTEGRATE and eight additional gene fusion detection methods, resulting in the validation of 138 gene fusions. Gene fusion candidates nominated by INTEGRATE using default
parameters and a threshold of one encompassing RNA-seq read (1-En) are shown on the left, whereas candidates nominated by eight additional programs,
and not INTEGRATE (“non-INTEGRATE”), are shown on the right. See Supplemental Figure 2 for tiers of INTEGRATE. In each category, gene fusion candidates are further divided into rearrangement classes: inter-chromosomal (blue shade) and intra-chromosomal (yellow shade), and sorted in descending
order of total RNA-seq read support (dark red bar—encompassing RNA-seq reads; green bar—spanning RNA-seq reads). Previously reported gene fusions
are written at the top of the bars. In the lower panel, each row corresponds to the gene fusion candidates nominated by each program. INTEGRATE,
Comrad, BreakTrans, and nFuse use both RNA-seq and WGS data. INTEGRATE is shown using the RNA-seq alignments from GSNAP, TopHat2, and
STAR, separately. ChimeraScan, Tophat-Fusion, FusionCatcher, pyPRADA, and TRUP use only RNA-seq data. Red boxes indicate nominated gene fusions
that were experimentally validated, black boxes indicate nominated gene fusions that did not have validation read support, and the lack of a red or black
box indicates an algorithm did not nominate the gene fusion candidate.

Table 2 for validated fusion junctions), of which 123 are called by
INTEGRATE using default parameters (two encompassing RNA-seq
reads), nine can be detected by INTEGRATE using one encompassing RNA-seq read, and only six were not detected by INTEGRATE.
Next, we used the 138 validated gene fusions discovered using nine methods as the gold standard for comparing the sensitivity and precision of each method as shown in Figure 3. The
combined set of INTEGRATE gene fusion predictions using all
three alignment tools has the highest sensitivity (89%) while
maintaining a high precision (81%). While the default parameters
for INTEGRATE require two encompassing RNA-seq reads, a user
could modify this threshold to one encompassing RNA-seq read,
which had a sensitivity of 95.6% (132/138). Interestingly, while
INTEGRATE only missed six validated fusions (out of 138), none
of the other programs successfully detected all of the six remaining
candidates (Fig. 2), indicating that a user would have to use multiple programs to detect all of the gene fusions. We also found variation based on the alignment tool used. The sensitivity of running
INTEGRATE with default parameters using a single alignment tool
is 67% for GSNAP, 46% for TopHat2, and 42% for STAR, while
maintaining high precision of 85%, 93%, and 85%, respectively.
Even when INTEGRATE uses STAR, which had the worst performance of the alignment tools, it still outperformed the next best
program, nFuse, which discovered 45 gene fusions but missed

93 gene fusions resulting in a 33% sensitivity and 44% precision.
ChimeraScan has a slightly lower sensitivity (29%) than nFuse
but has a higher precision of 74%. FusionCatcher has an even
lower sensitivity (25%) but a higher precision (95%). The remaining five methods (TopHat-Fusion, pyPRADA, TRUP, Comrad, and
BreakTrans) have sensitivities lower than 10%. TRUP, Comrad,
and BreakTrans all have a precision of 100%; however, they miss
more than 132 validated gene fusions. Overall, the accuracy (F1
score) of INTEGRATE, based on the combination of sensitivity
and precision, is the highest of all nine tools (Fig. 3).
Overall, INTEGRATE is a highly sensitive method, resulting in
the discovery of an additional 125 gene fusions that eluded earlier
studies. Interestingly, all of the previously discovered gene fusions have more than five supporting RNA-seq reads (Fig. 2;
Supplemental Table 1) with a maximum of 306 supporting RNAseq reads. In contrast, most of the newly discovered fusions have
low expression levels, as exemplified by 85 out of the 138 fusions
having ≤5 RNA-seq reads and 44 of these 85 gene fusions having
only one spanning read. Additionally, as shown in Figure 2, the
eight additional programs typically detect the more highly expressed gene fusions, whereas the gene fusions with lower expression levels are typically missed by more methods. For example, the
most highly expressed of the seven previously reported gene fusions, EIF3K-CYP39A1 (283 reads), PLA2R1-RBMS1 (306 reads),
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Overall, we found that INTEGRATE
only missed six candidates; however,
none of these predictions were found to
have a high level of read support (all
have <5 reads). Additionally, the six gene
fusions missed by INTEGRATE were
not nominated by a single program but
were nominated by one of four programs
(nFuse, ChimeraScan, FusionCatcher,
and pyPRADA). Conversely, the other
four programs (TopHat-Fusion, TRUP,
Comrad, and BreakTrans) did not identify
any validated gene fusions that were
missed by INTEGRATE.

Application to TCGA breast cancer
patient cohort
Next, we applied INTEGRATE to a cohort
of 62 breast cancer patients (Supplemental Table 4), generated by The Cancer
Figure 3. Comparison of INTEGRATE and eight additional fusion calling methods. Sensitivity and precision (red bar and blue bar, respectively) of each method were calculated using a gold standard, which is
Genome Atlas (TCGA) Research Netthe experimentally validated gene fusion called by nine methods, sorted in decreasing order of sensitivity.
work (http://cancergenome.nih.gov/), that
INTEGRATE applied with default parameters, using aligned reads generated by GSNAP, TopHat2, and
had both whole-genome and RNA-seq
STAR is indicated by G, T, and S, respectively. The combination of the three alignment tools is indicated
data available (The Cancer Genome Atlas
by C. The accuracy, or F1 score, based on the combination of sensitivity and precision is shown with a
Network 2012). INTEGRATE discovered
green triangle.
347 gene fusions involving both WGS
and RNA-seq read support and 132 nonand RAB7A-LRCH3 (80 reads), are detected by seven, six, and seven
read-through gene fusions with only RNA-seq reads (Supplemenmethods, respectively. EFTUD2-KIF18B (20 reads), FOSL2-BRE (47
tal Table 4). This revealed eight recurrent gene fusions, six
reads), and ERO1A-FERMT2 (nine reads) were found by three,
of which (DCAF6-MPZL1, ESR1-CCDC170, KANSL1-ARL17A,
three, and two methods, respectively. However, the lowly exRPS15A-ARL6IP1, STAT3-PTRF, and TANGO6-CDH1) were reconpressed gene fusion HNRNPUL2-AHNAK, having only six supportstructed by INTEGRATE with the fusion junctions and genomic
ing reads, is only detected by INTEGRATE. Interestingly, while
breakpoints (Fig. 4). SLC22A20-HORMAD1 and SCARB1-UBC were
INTEGRATE shows increased sensitivity, as exemplified by its abilcalled by only supporting RNA-seq reads (Fig. 4). The most frequent
ity to detect lowly expressed gene fusions compared to other methgene fusion, KANSL1-ARL17A/ARL17B, has been recently reported
ods, it also discovered highly expressed gene fusions that were
(Wen et al. 2012). Additionally, the estrogen receptor gene fusion
missed by other methods. For example, INTEGRATE was the
ESR1-CCDC170 (Fig. 5A,B) was recently reported in breast cancer
only method that detected the Tier 1 gene fusion MAVS-PANK2
(Sakarya et al. 2012).
(Supplemental Fig. 5) that has 38 supporting RNA-seq reads.
In addition to recurrent gene fusions, we hypothesized that
We also compared the RNA-seq expression levels with the
there may be a selective pressure to alter a gene in order to achieve
read support from cDNA-Capture, revealing a positive correlation
a similar molecular consequence, as exemplified by ETS family
(0.95) (Supplemental Fig. 6). This shows that gene fusion validamembers (Papas et al. 1989), BRAF (Stratton et al. 2004), MAST/
tion, similar to RNA-seq, is also heavily dependent on the expresNOTCH (Robinson et al. 2011), which we refer to as being functionsion of the gene fusion transcript. Therefore, it is unclear whether
ally recurrent. Therefore, we sought to identify genes that are inlow-expressing gene fusions predicted by INTEGRATE that were
volved in multiple fusions with the breakpoint occurring with
not validated are actually false positives or whether additional valthe same 5′ or 3′ exon. We found eight conserved 5′ genes and
idation sequencing would eventually confirm their presence as
14 conserved 3′ genes representing 51 non-read-through gene fufound by RNA-seq data. In contrast, 60 of the 71 gene fusion cansions across 25 patients (Fig. 4). Many of these genes have been
didates that did not validate and were nominated by other methpreviously reported as gene fusion partners in breast cancer, e.g.,
ods, but not by INTEGRATE, had ≥5 RNA-seq reads. Therefore,
RARA (Edgren et al. 2011), CDK12 (Asmann et al. 2011; Natrajan
the higher quantity of supporting RNA-seq reads coupled with
et al. 2014), FBXL20 (Mardis et al. 2009; Robinson et al. 2011;
lack of read support from cDNA-Capture further suggests that
Kalyana-Sundaram et al. 2012), GAB2 (Stephens et al. 2009),
these nominations are false positives.
PLXDC1 (Robinson et al. 2011), CTSD (Asmann et al. 2012),
In addition to discovering Tier 1 and 2 gene fusions accurately
EIF3H (Edgren et al. 2011; Kalyana-Sundaram et al. 2012), MGP
by combining RNA-seq and WGS data (38 out 40 [95%] are validat(Asmann et al. 2012; Kalyana-Sundaram et al. 2012), PPP1R1B
ed) (see Supplemental Table 3 for genomic breakpoints of Tier
(Robinson et al. 2011), and RAB6A (McPherson et al. 2011a).
1 gene fusions), INTEGRATE also reliably detected candidates supCloser examination of the genomic locations for the recurrent
ported only by RNA-seq reads. Eighty-five out of 111 Tier 3-nr gene
and functionally recurrent gene fusions reveals multiple hotspots
fusion candidates were validated, resulting in a precision of ∼77%.
of gene fusions (Fig. 5C) on Chromosomes 1, 11, and 17. In total,
Fifty-one out of the 85 (60%) validated Tier 3-nr gene fusions were
44 out of the 65 recurrent and functionally recurrent gene fusions
missed by all the other methods.
harbor partners that reside in these three commonly altered regions
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Figure 4. Recurrent and functionally recurrent gene fusions in a TCGA 62 breast cancer patient cohort. Gene fusions are listed in the order of recurrent,
5′ functionally recurrent, and 3′ functionally recurrent. The first column shows the 5′ genes and the second column shows the 3′ genes. The third column is
the TCGA names of the samples. Bar chart in the fourth column shows the log scale value of the quantity of supporting RNA-seq reads for each gene fusion.

(Supplemental Table 5). There are three recurrent and functionally
recurrent gene fusions involving a gene in 1q21.3. Seventeen gene
fusions involve a gene residing in 11q13.1–11q14.1. Thirty-three
gene fusions involved a gene that resides in the consecutive region
of bands 17q11.2, 17q12, and 17q21–23. It is plausible that many of
these gene fusions may be passenger aberrations corresponding to
recurrent amplicons. However, a subset may represent potentially
relevant gene fusions in breast cancer as exemplified by ESR1 translocations (Veeraraghavan et al. 2014). Additionally, while the majority of gene fusions reside in commonly altered regions, there is

still a subset of recurrent and functionally recurrent gene fusions
that are not the by-product of a copy number event and therefore
may warrant further exploration.

Read-through transcription
INTEGRATE classifies a read-through as a chimera involving two adjacent genes on the same strand, with the 5′ gene being upstream,
but lacking any WGS read support. For example, INTEGRATE identified 288 read-throughs in HCC1395 cells and 453 read-throughs
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the first exon (Exon[1]), (2) the second to
the last exon (Exon[n−1], where n is the
number of exons), and (3) all other exons
(Exon[2:n−2]) with a 3′ gene involving either the second exon (Exon[2]) or any
downstream exons (Exon[3:n]). This revealed six classes: (I) Exon[n−1]-Exon[2];
(II) Exon[2:n−2]-Exon[2]; (III) Exon[n
−1]-Exon[3:n]; (IV) Exon[2:n−2]-Exon
[3:n]; (V) Exon[1]-Exon[2]; and (VI)
Exon[1]-Exon[3:n]. As shown in Figure
6A, we observed different patterns between gene fusions associated with genomic rearrangements and read-throughs.
The majority of Tier 1, 2, and 3-nr gene
fusions (38%–40%) belong to class IV
(Exon[2:n−2]-Exon[3:n]), which involves
random exons in the middle of the 5′ and
3′ fusion partners, in contrast to 7.2% of
read-throughs belonging to class IV.
Fifty-one percent of read-throughs belong
to class I (Exon[n−1]-Exon[2]), which involves the second to the last exon of a 5′
transcript and the second exon of a 3′ transcript. In contrast, only 4%, 6%, and 3% of
Tier 1, 2, and 3-nr fall into class I, respectively. Overall, the exon usage distribution of read-throughs is significantly
different from the Tiers 1, 2, and 3-nr
(Pearson’s χ2 test, each tier has a P < 2.2 ×
10−16), whereas Tier 2 and Tier 3-nr are
not significantly different from Tier 1
(P-values 0.32 and 0.17, respectively).
We were next interested in assessing
the recurrence of read-throughs relative
to gene fusions derived from genomic
events. As shown in Figure 6B, within
the 62 patient cohort, 98% of the nonread-throughs predicted by INTEGRATE
occur in a single patient, whereas only
46% of read-throughs are singletons
(Pearson’s χ2 test has a P < 2.2 × 10−16).
In addition to 54% of read-throughs occurring in multiple patients, we observed
eight read-throughs occurring in more
than 30 patients.

Figure 5. Hotspots of gene fusions in 62 TCGA breast cancer patients. (A) ESR1-CCDC170 fusion in
TCGA-A2-A0YG. (B) ESR1-CCDC170 fusion in TCGA-BH-A18R. ESR1 (red) and CCDC170 (blue) are on
the forward strand in region 6q25.1, and the 5′ gene ESR1 is downstream from the 3′ gene CCDC170.
The two fusions share the same 5′ exon at ESR1 (Exon 2 of transcript uc031sqe.1), but 3′ exons of
CCDC170 are different (Exons 2 and 3 of transcript uc003qol.3). (C) Circos plot of recurrent and functionally recurrent gene fusions detected by INTEGRATE. The green lines indicate inter-chromosomal gene fusions, and the blue lines indicate intra-chromosomal gene fusions. The names of the genes involved in
each fusion are plotted on the outside of the circle. The gene fusions associate with several hotspots
on Chromosomes 1, 11, and 17.

in a cohort of 62 TCGA patients (Supplemental Tables 6, 7). We examined the difference between gene fusions associated with
genomic rearrangements (Tiers 1, 2, and 3-nr) and read-throughs
(Tier 3-r) by classifying the patterns of exons involved in the fusion
junctions. This includes any combination of a 5′ gene involving (1)
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Discussion

INTEGRATE is a gene fusion discovery
tool that leverages both RNA-seq and
whole-genome data. By integrating orthogonal data sets, we demonstrate that
INTEGRATE is highly sensitive. This can
be exemplified by our discovery of 125
novel gene fusions in HCC1395 in addition to the previously discovered gene fusions reported by three earlier studies (Stephens et al. 2009;
Robinson et al. 2011; Kalyana-Sundaram et al. 2012). Many of
these gene fusions were expressed at very low levels. For instance,
INTEGRATE identified 45 gene fusions with only one fusion junction spanning the RNA-seq read. Due to their low read support,
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Figure 6. Different patterns between gene fusions and read-throughs. (A) Exons involved in gene fusions and read-throughs follow different patterns. A
gene fusion (or read-through) transcript can be categorized into six classes involving the first, second to last, or any other exon of the 5′ gene with either the
second or downstream exon of the 3′ gene. (B) Recurrence of gene fusions and read-throughs across 62 breast cancer patients. The horizontal axis is number of patients, and the vertical axis is fraction of events. Blue bars represent gene fusions and red bars represent read-throughs. The pie chart shows the
percentage of singleton gene fusions (left) and read-throughs (right).

these gene fusions are difficult to detect and may even be filtered
by other programs depending on a minimum read support threshold to nominate a fusion. Furthermore, the sensitivity of
INTEGRATE revealed low-expressing gene fusions that may have
been expressed below a level of detection with the current validation sequencing depth. Unlike DNA-based validation, where we
would expect more uniform coverage, the ability to detect and validate expressed gene fusions is highly dependent on expression.
Our validation data could underrepresent the accuracy of
INTEGRATE, and additional sequencing may confirm the presence
of the remaining candidates.
One major reason (other than orthogonal data sets) for the
improved sensitivity and accuracy of INTEGRATE is that we use a

gene fusion graph that enables us to conduct alignment steps
targeting specific gene nodes. In contrast to mapping the true
positive spanning RNA-seq reads against the whole genome or
whole transcriptome, reducing the search space to only a few relevant genes that may be involved in a gene fusion event increased
sensitivity by (1) allowing for the alignment to shorter flanking
regions of the spanning RNA-seq reads, (2) tolerating more mismatches and gaps in the alignments, and (3) avoiding false positive
alignments that would have occurred outside of the relevant gene
nodes caused by repeats and sequencing errors. Furthermore,
INTEGRATE uses multiple realignment steps against a small number of relevant gene nodes to reduce false-positive encompassing
and spanning reads to achieve a more accurate rate in discovering
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gene fusions. Interestingly, while INTEGRATE was designed with
the intent of using both WGS and RNA-seq data, we found that,
in the absence of WGS data, INTEGRATE can still be applied to
find high-quality gene fusion candidates using only RNA-seq
data. This is likely due to the thorough realignment steps to filter
inaccurate alignments that may introduce false-positive gene fusion predictions.
INTEGRATE is also designed to be highly efficient due to multiple design aspects. First, the fusion gene graph that connects the
gene nodes guarantees only the relevant RNA-seq reads, i.e., discordant encompassing reads mapped to two genes and spanning
reads with their anchors in the graph, undergo thorough alignment and realignment steps. Second, alignments and realignments in gene nodes are performed on the BWTs of the gene
nodes with time complexity linear of read length. Third, integration of WGS data is guided by the RNA-seq gene fusion candidates.
Only relevant encompassing and spanning WGS reads residing
within focal regions near the candidate fusion junctions are considered for detecting SVs.
Currently, only a few existing computational tools focus on
using combined data with the intent of balancing sensitivity and
specificity. To discover gene fusion candidates, Comrad was designed to simultaneously analyze encompassing, but not spanning, WGS and RNA-seq reads. However, spanning reads offer
significant evidence for nominating candidates that can help balance specificity and accuracy. This also represents a significant limitation for being able to reconstruct the genomic breakpoint or the
fusion junction accurately. nFuse has a higher sensitivity (33%)
than all the other programs evaluated other than INTEGRATE;
however, it also had the most nominations of any program
(Fig. 2; Supplemental Fig. 3). This is not surprising as nFuse was intended to identify complex genomic rearrangements. Lastly, as
BreakTrans integrates SV and gene fusion predictions called by separate tools, its overall performance relies on the sensitivity and accuracy of each individual tool run separately. This will therefore
miss low-expressing gene fusions or low-frequency genomic
events that are detectable by using orthogonal applications but
are not easily detected by either RNA-seq or WGS alone.
Additionally, gene fusions with strong transcriptome read support
but no genomic evidence potentially due to lack of coverage, highly repetitive sequence, or representing an RNA chimera (i.e., readthrough, trans-splicing events) will be missed by requiring both
RNA-seq and WGS evidence. Taken together, our comparative
analyses demonstrate the clear advances that INTEGRATE has
achieved in gene fusion discovery from NGS data.
Unlike many gene fusion prediction tools that ignore readthrough or trans-splicing events, INTEGRATE is able to provide
valuable insight into RNA chimeras. For instance, RNA callers categorize read-throughs purely based on their close proximity and
orientation but have no definitive way to discriminate between a
genomic or transcriptomic event in the absence of genomic data.
However, INTEGRATE can identify events that may be classified
as read-throughs based on genomic location but in fact are due
to a genomic deletion. This in turn could have important implications in the underlying biology. For instance, we have shown that
read-throughs have different patterns of exon usage and prevalence across patients compared to genomic-based events. First,
the patterns of exon utilization support that read-throughs are
due to splicing of a 3′ exon in the 5′ partner to a 5′ exon of the
3′ gene partner. In contrast, genomic-based gene fusions appear
to occur more randomly. Second, read-throughs appear to be recurrent whereas genomic events are typically patient-specific. Of
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the few recurrent genomic events, they typically occur in a small
subset of patients, whereas read-throughs were observed in up
to 30+ patients. Taken together, the ability to distinguish a
genomic event from a common read-through event could reveal
genomic mutations that could serve as valuable biomarkers.
INTEGRATE has also been implemented to improve the interpretation of gene fusion discovery. First, we have established a tier
structure that incorporates the level of data support from RNA-seq
and WGS data. This in turn provides more confidence beyond the
total number of reads that support a particular candidate. For instance, a gene fusion with encompassing and spanning WGS
and RNA-seq reads would be considered a reliable candidate compared to a candidate with only RNA-seq encompassing reads.
Second, INTEGRATE is able to provide candidate gene fusion junctions at single-base resolution and the exact genomic breakpoints
if spanning WGS reads were detected. Sequences and locations of
the involved exons of the fusion junctions are provided to facilitate subsequent functional analysis and experimental validation.
This also facilitates downstream analysis, such as finding complex gene fusions involving more than two genes, as exemplified
by the seven instances observed in the cohort of 62 TCGA breast
cancers (Supplemental Fig. 7). Furthermore, INTEGRATE is capable of detecting multiple alternative splicing isoforms for a fusion gene. For instance, of the seven previously discovered gene
fusions in HCC1395, three of these gene fusions were captured
by INTEGRATE with multiple isoforms (four isoforms for EIF3KCYP39A1, three isoforms for RAB7A-LRCH3, and two isoforms
for HNRNPUL2-AHNAK). This is important to ensure that an isoform producing a potentially in-frame novel protein is not
overlooked.
Prior to this study, only a small number of gene fusions had
been experimentally validated in the HCC1395. However, following our comprehensive analysis and validation, we have confirmed a large quantity of gene fusions. It is likely due to a
number of factors. First, this is the most comprehensive analysis
of this cell line conducted to date. Second, INTEGRATE was able
to detect gene fusions missed by multiple programs suggesting
that INTEGRATE is more sensitive and earlier analyses underrepresented the total number of gene fusions in a given sample. Third, a
large portion of the HCC1395 cell line genome harbors copy number variation (Supplemental Fig. 8). As breast cancer gene fusions
have been associated with copy number variation (KalyanaSundaram et al. 2012), it is not surprising that 106 (77%) of the
138 validated gene fusions have one or both genes residing in an
amplicon. In total, 143 (59%) out of 276 genes involved in the
138 validated gene fusions reside in the amplicons, which is significantly higher (Pearson’s χ2 test, P = 2.35 × 10−6) than the percentage of expressed genes residing in amplicons (FPKM ≥ 0.1; 6871
[38%] out of 18,235).
The application of INTEGRATE to a breast cancer cohort enabled the identification of novel gene fusions, a subset of which
were recurrent. Interestingly, among the recurrent fusion candidates, ESR1 translocations (Figs. 4, 5) have been reported to be involved in hormone therapy resistance, exemplifying the potential
biological significance of these candidates (Li et al. 2013). ESR1CCDC170 was recently reported to markedly increase cell motility
and anchorage-independent growth, reduced endocrine sensitivity, and enhanced xenograft tumor formation (Veeraraghavan
et al. 2014). The mechanistic studies suggest that CCDC170 engages the GAB1 signalosome to potentiate growth factor signaling and
enhance cell motility (Veeraraghavan et al. 2014). Additionally,
STAT3-PTRF has been reported to be present in uterus/cervix
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cancer (Ojesina et al. 2014). Furthermore, many of the functionally recurrent gene fusions found by INTEGRATE involve genes related to previously reported fusions in breast cancer. Overall, given
the high accuracy of INTEGRATE in detecting gene fusions, the locations of the nominated fusions are in hotspots of breast cancer,
and many of the gene fusion partners have been previously implicated in breast cancer, it is possible that some of the remaining
INTEGRATE recurrent and functionally recurrent gene fusion
nominations may also be relevant to breast cancer progression.
Overall, based on our comparison of nine tools, INTEGRATE
provides a significant advance, balancing sensitivity and specificity
for improved gene fusion discovery. Various factors such as
artifacts, low data coverage, mapping errors, repetitive regions,
and low expression levels hinder the ability of using only WGS
SV prediction or RNA-seq fusion detection strategies. Therefore,
INTEGRATE takes advantage of both strategies due to the increasing availability of both whole genome and transcriptome sequencing data from the same patient to provide a highly accurate method
for gene fusion discovery to unveil novel causative mutations.

Methods
INTEGRATE fusion calling using both RNA-seq
and WGS data
Supplemental Figure 9 provides a detailed overview of
INTEGRATE. The first step of INTEGRATE is to systematically store
all of the encompassing reads aligned by a RNA-seq reads mapping
tool in a graph where the nodes correspond to genes and the edges
connect two genes involved in a putative fusion. At this point, the
graph can be very dense, and INTEGRATE uses a series of filtering
steps to remove false-positive gene fusion candidates according to
the concordant suboptimal alignments and repetitiveness of the
paired-end reads in the graph (Supplemental Methods). Next,
INTEGRATE leverages the fusion gene graph that has been
built to conduct a targeted split-read alignment to map either
spanning reads or suboptimal concordant reads systematically in
a single step instead of using two independent procedures (Supplemental Methods). If provided with WGS data sets, INTEGRATE attempts to identify SVs supporting the fusion candidates by
alignment in focal regions (Supplemental Fig. 10; Supplemental
Methods).
Due to the large quantity of encompassing reads that are realigned, coupled with unmapped reads that are evaluated as spanning reads, we implemented a fast split-read mapping algorithm.
A BWT is created for each gene node (including exons and introns)
(Supplemental Fig. 1) so that the prefix trie of each gene node can be
simulated. A dynamic programming algorithm is designed to perform local alignment between a split-read and the prefix trie using
a breadth first search that extends on the prefix trie according to the
number of differences (mismatches and indels) of the best matches
(highest scores in the dynamic programming). Pseudo code of the
algorithm is given in Supplemental Figure 11, and details of the algorithm are explained in Supplemental Methods. The fast split-read
mapping algorithm for aligning and realigning RNA-seq reads and
the fast split-read mapping algorithm for aligning WGS reads in focal regions enable INTEGRATE to perform efficiently in run time
(Supplemental Fig. 12). INTEGRATE also has a moderate space usage (Supplemental Fig. 12).

Validation of gene fusions in HCC1395 cell line
To enrich for the highest quality gene fusion predictions in our
tool comparison, gene fusions with canonical exonic boundaries

called by INTEGRATE and eight additional fusion calling methods
(Comrad, nFuse, BreakTrans, TopHat-Fusion, ChimeraScan,
FusionCatcher, pyPRADA, and TRUP) are considered as gene fusion candidates after additional filtering to remove false-positive
candidates (i.e., gene fusions involving transcript variants such
as HLA-A>>HLA-C, read-throughs, genes with overlapping isoforms) (Supplemental Fig. 3). For each gene fusion candidate,
two sequencing probes were designed near the fusion junction.
One probe was designed in the 5′ gene and the second probe was
designed in the 3′ gene. For gene fusions with multiple fusion
junctions corresponding to the alternative splicing of each gene
fusion partner, we chose probes corresponding to the isoform
with the greatest read support. All probes for the 240 gene fusion
candidates are summarized in Supplemental Table 8 with their corresponding genes. Following cDNA hybridization, as previously
described (Cabanski et al. 2014), ∼10 million 2 × 250 paired-end
reads were generated using MiSeq. These reads were aligned using
BWA to the predicted gene fusion junctions. The number of targeted validation reads spanning fusion junctions, with a conservative
threshold of requiring the smaller flanking region to be longer
than 30 nt, are summarized in Supplemental Table 9.

Application of INTEGRATE on TCGA human patient cohort
We downloaded whole-genome and RNA-seq data of 62 TCGA
breast cancer patients. On average, INTEGRATE uses 8 h to process
data for one patient (minimum was 1 h and maximum was 78 h).
Average memory is 30 GB with a minimum of 24 GB and a maximum of 49 GB. When a gene fusion was predicted as a genomic
event (intra- or inter-chromosomal) and a read-through event in
multiple patients, then only if the percentage of patients with an
intra- or inter-chromosomal gene fusion was >80% was it reported
as a genomic fusion. For the less recurrent chimeras that could be
explained as read-throughs or genomic events (due to false-positive encompassing WGS reads, medium-size deletions, or lack of
WGS reads), three steps are performed before classifying them as
genomic or read-through events. First, the two genes are >1 Mb
apart. Second, for chimeras with genes closer than 1 Mb, the size
of the deletions must be longer than 5000 nt. Third, if the fusion
junction involves the second to last exon of the 5′ gene fusing
into the second exon of the 3′ gene, characteristic of splicing
that occurs in read-through transcripts, then we consider them
as read-throughs.

Data access
The sequence data from this study have been submitted to the NCBI
BioProject database (http://www.ncbi.nlm.nih.gov/bioproject/)
under accession number PRJNA201238. The INTEGRATE software
can be downloaded from SourceForge (https://sourceforge.net/
projects/integrate-fusion/), and the source code is available in the
Supplemental Material.
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